Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Bristol-Myers Squibb
Daiichi Sankyo
AstraZeneca
BicycleTx Limited
AstraZeneca
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Astellas Pharma Inc
G1 Therapeutics, Inc.
Merck Sharp & Dohme LLC
Toray Industries, Inc
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
SWOG Cancer Research Network
Emory University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Xennials Therapeutics Australia Pty Ltd
University Health Network, Toronto
Celgene
Karolinska University Hospital
Cardiff University
Yale University
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Pierre Fabre Medicament
University of Michigan Rogel Cancer Center
Valerio Therapeutics
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
SWOG Cancer Research Network
SWOG Cancer Research Network
National Cancer Institute (NCI)